Skip to main navigation
Ardelyx logo2
  • Who We Are
  • Our Science
  • Our Pipeline
  • Patients & Families
  • Investors
  • Join Us
  • MENU
  • HOME
Select Page

PRESS RELEASES

  • IR HOME
  • NEWS & EVENTS
    • OVERVIEW
    • PRESS RELEASES
    • EVENTS & PRESENTATIONS
  • STOCK INFORMATION
    • OVERVIEW
    • HISTORIC STOCK LOOKUP
    • INVESTMENT CALCULATOR
    • ANALYST COVERAGE
  • FINANCIALS & FILINGS
    • OVERVIEW
    • SEC FILINGS
  • CORPORATE GOVERNANCE
    • OVERVIEW
    • MANAGEMENT
    • BOARD OF DIRECTORS
    • COMMITTEE COMPOSITION
  • CONTACT IR
  • IR HOME
  • NEWS & EVENTS
    • OVERVIEW
    • PRESS RELEASES
    • EVENTS & PRESENTATIONS
  • STOCK INFORMATION
    • OVERVIEW
    • HISTORIC STOCK LOOKUP
    • INVESTMENT CALCULATOR
    • ANALYST COVERAGE
  • FINANCIALS & FILINGS
    • OVERVIEW
    • SEC FILINGS
  • CORPORATE GOVERNANCE
    • OVERVIEW
    • MANAGEMENT
    • BOARD OF DIRECTORS
    • COMMITTEE COMPOSITION
  • CONTACT IR

PRESS RELEASES

Press Releases
Date Title
Feb 12, 2018 Ardelyx Announces Departure of Chief Scientific Officer
Feb 8, 2018 Ardelyx to Participate in Leerink Partners 7th Annual Global Healthcare Conference
Jan 3, 2018 Ardelyx Announces Presentation at J.P. Morgan 36th Annual Healthcare Conference
Jan 3, 2018 Ardelyx Successfully Completes T3MPO-3 Safety Extension Study of Tenapanor for IBS-C
Dec 11, 2017 Ardelyx Announces License Agreement with Shanghai Fosun Pharmaceutical Industrial Development Company Limited for Tenapanor in China
Nov 28, 2017 Ardelyx and Kyowa Hakko Kirin Announce License Agreement for Tenapanor for Cardiorenal Diseases in Japan
Nov 21, 2017 Ardelyx Announces Updated Development Path for its Cardiorenal Pipeline
Nov 7, 2017 Ardelyx Reports Third Quarter 2017 Operating Results and Clinical Progress
Oct 16, 2017 Ardelyx Announces Tenapanor Reduces Pain Caused by IBS-C Through Inhibition of TRPV-1 Signaling
Oct 11, 2017 Ardelyx's Pivotal Phase 3 Study of Tenapanor for IBS-C Hits Primary and All Secondary Endpoints to Support NDA Submission in 2018

Pagination

  • First page « first
  • Previous page ‹ previous
  • …
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Current page 7
  • Page 8
  • Page 9
  • Page 10
  • Page 11
  • …
  • Next page next ›
  • Last page last »
FAQs
Email Alerts
Connect

Bay Area
34175 Ardenwood Boulevard
Fremont, CA 94555

Boston Area
200 West Street, 4th Floor
Waltham, MA 02451

Phone: 510.745.1700

Inquiries:
General: info@ardelyx.com
Media: media@ardelyx.com
Investor: investor@ardelyx.com
Business Development: partnering@ardelyx.com

  • Follow
  • Follow

© 2021 Ardelyx®
Terms & Conditions · Privacy Policy
Expanded Access · Forward Looking Statements

SITE DESIGN BY D&CO
  • Facebook
  • LinkedIn
  • Twitter
  • RSS